Finance
Verizon Shares Take a Hit After Q1 Sales Warning
March 13, 2025
Think your December was hectic? The Trans-Siberian Orchestra's holiday tour shattered expectations, with the band performing 70 shows last month, sometimes even squeezing in four performances a day. This intense schedule helped them claim the title of the top-grossing tour for the month by a wide margin.
On the stock market front, US indices brushed off concerns over Trump’s tariff announcement, closing higher yesterday. Both the S&P 500 and Nasdaq 100 gained 0.5%. The utilities sector led the S&P 500 ETFs, but every sector wrapped up the day in the green.
With the release of the iPhone 16, Apple aimed to revolutionize its flagship product by integrating artificial intelligence, but it seems the new AI features weren’t enough to spark the long-awaited upgrade cycle. The company reported a nearly 1% drop in iPhone revenue, totaling $69.1 billion during the critical holiday quarter—falling short of analysts’ expectations for a 1.4% increase.
Apple’s AI capabilities, especially with Siri, have yet to impress, with some reports indicating the virtual assistant has become less useful. As a result, the new AI-driven iPhone hasn’t been the sales boost Apple hoped for, despite iPhones accounting for about half of its revenue.
On the positive side, Apple’s relatively low profile in the AI race has actually worked in its favor amid this week’s downturn in AI-related tech stocks. The company has reclaimed its status as the world’s most valuable company. However, this hasn’t shielded its stock from a wave of recent downgrades.
Key Takeaway:
Despite the mixed reception for its AI efforts, CEO Tim Cook reminded investors that “Apple is reporting our best quarter ever, with revenue of $124.3 billion, up 4% from a year ago.” This serves as a reminder that Apple’s success extends beyond iPhones, with its services sector playing a crucial role in driving growth. While the company may not be delivering groundbreaking new moments like “And one more thing,” it’s continuing to perform strongly with its established offerings and generate significant profits.
Presented by Boxabl
You must be doing something right if the biggest names in your industry take an interest.
That’s the story with BOXABL. They’ve rethought housing by bringing assembly lines to new home construction. Not to mention, the company has gained the attention of investors like D.R. Horton.
Where traditional homes take over 7 months to build, BOXABL factories can mass produce their signature Casita home in nearly four hours, plumbing, electrical, HVAC, and all. 190,000+ potential buyers already reserved one1 and they’re just getting started.
Now, everyday investors can join them too. When BOXABL last opened a Reg A investment opportunity, they maxed out the $75M regulatory limit. Become an investor today.2
If Robert F. Kennedy Jr. clears the Senate confirmation process, his leadership could bring sweeping changes to the Department of Health and Human Services. Even former President Trump has hinted that Kennedy is poised to make bold moves, though the nation remains sharply divided over whether the vaccine skeptic’s proposals will actually benefit public health.
One of Kennedy’s most significant proposals — banning pharmaceutical ads — could send shockwaves through the industry, potentially redirecting billions in advertising dollars.
The Power of Pharma Advertising: TV ads have proven to be effective. After the FDA relaxed regulations in 1997, allowing drug companies to only list the major side effects of their products, pharmaceutical ad spending exploded. In 1997, only 79,000 drug commercials aired on US TV; by 2016, that number had skyrocketed to 663,000.
Key Takeaway:
While RFK Jr.’s stance on vaccines and other health matters remains controversial, many consumers are less than thrilled by the constant barrage of side effects in pharmaceutical ads. Still, with vast financial interests on the line, the advertising and pharmaceutical industries will fight tooth and nail to maintain their influence. How this all plays out is still uncertain.
Presented by Boxabl
When the biggest names in your industry take an interest, you know you're onto something.
That's the story with BOXABL. They're bringing assembly lines to home construction, gaining the attention of investors like D.R. Horton. Where traditional homes take 7+ months to build, BOXABL is capable of producing their signature “Casita” in 4 hours.And they’re just getting started. BOXABL just announced a new $20,000 housing unit called “Baby Box”. It’s a turn-key home designed for affordability and versatility, with applications spanning workforce accommodations to tiny homes.
Now, everyday investors can join them too. When BOXABL last opened a Reg A investment opportunity, they maxed out the $75M regulatory limit. BOXABL believes their new $20,000 house is the key to unlocking even greater potential.
Advertiser's disclosures:
¹ The minimum investment is $1,000. This is a paid advertisement for the Boxabl Inc. Regulation A offering. Please read the offering circular and related risks at StartEngine’s Boxabl Website.
Investing in private company securities is not suitable for all investors because it is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities.
